Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase 1 Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors

This is a phase 1, first-in-human, open-label, dose-escalation study of XB628, a first-in-class bispecific antibody natural killer (NK) cell engager that targe…

Solid TumorAdvanced Solid TumorMetastatic Solid Tumor+1 more

ExelixisNCT06952010